UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma

Completed · Not applicable

Conditions studied: MULTIPLE MYELOMA

In brief

To evaluate changes in coagulation (blood clotting) factors and platelet function in multiple myeloma participants undergoing VELCADE treatment for the first time.

Key facts

Study ID

NCT00569868

Run by

University of Arkansas

People needed

11

Starts

2005-08-01

Expected to finish

2008-01-01

Last updated by the study team

2011-08-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patients with myeloma who had relapsed after one prior treatment and who have demonstrated resistance to their last treatment, who are candidate to receive Velcade and had normal PT and PTT, will be evaluated for inclusion in the present study.

You may not qualify if…

• Previous history of venous thromboembolism, myocardial infarction, stroke, TIA
• Hypercoagulable state (deficit ATIII, Factor V Leiden, deficit protein S, deficit protein C, prothrombin gene mutation), antiphospholipid syndrome.
• Von Willebrand disease, inherited platelet abnormalities.
• Familiar history of hypercoagulable state.
• Anticoagulant therapy, aspirin, non-steroidal anti-inflammatory drugs, beta blockers, tricyclic antidepressant, hormone replacement therapy, BCPs, and all other agents able to interfere with platelet function in the previous two weeks.
• Non-secretory MM, unless the patient has measurable lesions on CT, MRI and/or PET.

Where it is running

• University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.